Bashank Nahla, Sharef Seham, Mohran Taha Zaki, Khalil Maha
Department of Clinical Oncology and Nuclear Medicine, Assiut University Hospital, Assiut University, Assiut, Egypt.
Radiotherapy and Nuclear Medicine Unit, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
EJNMMI Rep. 2024 Apr 15;8(1):8. doi: 10.1186/s41824-024-00200-0.
To evaluate the efficacy of PET/CT usingF-FDG (F-fluorodeoxyglucose) as a radiotracer compared to conventional bone marrow biopsy (BMB) in detecting infiltration to bone marrow (BM) in pediatric patients with lymphoma at the time of initial diagnosis.
66 pediatric patients with lymphoma (47Hodgkin's and 19non-Hodgkin's lymphoma) were referred for initial staging byF-FDG PET/CT study. All patients underwent bilateral iliac BMB and F-FDG PET/CT scan with no more than 2 weeks interval in-between. Follow-up for at least 6 months was used as a reference standard to compare diagnostic performance between two modalities in detecting bone marrow infiltration (BMI).
Sensitivity, specificity, accuracy, as well as positive and negative predictive values of F-FDG PET/CT in detecting BMI were (80%, 86%, 85%, 63%, and 94%) in contrast to BMB (80%, 53%, 59%, 33%, and 90%) respectively. F-FDG PET/CT was concordant to BMB in 39/66 patients (59%).
F-FDG PET/CT was more accurate and specific, with higher predictive values than BMB in detecting BMI during initial staging of pediatric lymphoma. In most pediatric lymphoma patients, F-FDG PET/CT can be used instead of BMB to determine BMI during their initial staging process.
评估以F-FDG（氟代脱氧葡萄糖）作为放射性示踪剂的PET/CT与传统骨髓活检（BMB）相比，在初诊时检测小儿淋巴瘤患者骨髓浸润的疗效。
66例小儿淋巴瘤患者（47例霍奇金淋巴瘤和19例非霍奇金淋巴瘤）接受F-FDG PET/CT检查进行初始分期。所有患者均接受双侧髂骨骨髓活检及F-FDG PET/CT扫描，两者间隔不超过2周。以至少6个月的随访作为参考标准，比较两种检查方法在检测骨髓浸润（BMI）方面的诊断性能。
F-FDG PET/CT检测BMI的灵敏度、特异度、准确度以及阳性和阴性预测值分别为（80%、86%、85%、63%和94%），而BMB分别为（80%、53%、59%、33%和90%）。F-FDG PET/CT与BMB结果在39/66例患者（59%）中一致。
在小儿淋巴瘤初始分期时，F-FDG PET/CT在检测BMI方面比BMB更准确、特异，预测值更高。在大多数小儿淋巴瘤患者的初始分期过程中，F-FDG PET/CT可用于替代BMB来确定BMI。
